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In light of drastically escalating costs for today’s medications, pharmacy benefit 
managers are seeking a constant balance of effectiveness and cost control.  Step Therapy 
helps to address these concerns with a try medication “A” before medication “B” logic.  
Like all medical interventions, the possibility of unintended consequences exists.  The 
purpose of this study was to determine if non-adherence results from application of Step 
Therapy for selected medication classes (antihyperlipidemics (specifically the HMG Co-
A reductase inhibitors), angiotensin receptor blockers, uro-selective alpha-blockers, and 
dipeptidyl peptidase-4 inhibitors) in the Department of Defense. 
Using a retrospective database analysis, this study examined the primary 
adherence rate of subjects after they have been denied coverage due to Step Therapy 
intervention.  Additionally, this study examined the association of demographic and 
service-related factors with the likelihood that a patient will be non-adherent after 
encountering the intervention.  Finally, the study measured the time to adherence after 
intervention for those who were persistent after a Step Therapy claim rejection. STATA 
 vii 
version 10.0 was used to conduct logistic regression analyses to meet the study 
objectives. 
After examination of 279,508 claims for 27,202 subjects, the estimated primary 
non-adherence rate following the Step Therapy intervention for all medication classes 
combined was 15.1%.  Additionally, there was inter-class variability in this rate ranging 
between 13.1% and 19.5%.  A statistical and practical difference was also noted in non-
adherence rates between subjects who received care at the retail point of service versus 
those who received care at the mail order point of service.  Subjects who received care 
through retail were nearly twice as likely to be non-adherent as those who received care 
in the mail order segment.  For those subjects who were persistent with therapy, the 
median time-to-fill was estimated at 7 days. 
The occurrence of non-adherence following a Step Therapy intervention was 
clearly demonstrated through this study.  Although this study provides good framework 
for designing interventions after claim rejection, further research would help to determine 
the health impact of  primary non-adherence as well as the economic consequences of the 
intervention.   
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Chapter One: Introduction 
With increasing drug benefit costs, insurers have continued to introduce new 
methods to ensure appropriate care for patients while at the same time providing the best 
value for their policy holders.  These methods include restrictions on medication 
availability sometimes accompanied by educational interventions.  The cost-saving 
interventions focused on limiting access to medications include use of formularies, tiered 
formularies, Prior Authorization (PA), and Step Therapy. 
 While outside the scope of this review, it is worth noting even the most basic 
intervention, restrictive formularies, are themselves not without contention.1  The tiered 
formulary concept is an advancement on the basic formulary concept and is employed by 
some pharmacy benefit managers (PBMs) as an enforcement tool for implementation of 
other interventions.  Additional, advanced interventions including quantity limits, 
therapeutic interchange, drug utilization review, drug rebates and medication therapy 
management (MTM) are sometimes employed as cost-saving or quality improvement 
measures.  These items, however, are more health care provider-focused, involving less 
direct patient effort than the items described in this review.  
 Previous review articles published on PA and Step Therapy interventions have 
primarily focused on assessing cost-savings and identifying areas of future research.2-9  
Only a few of these articles include data on unintentional outcomes.  Unintentional 
outcomes in this setting may include adverse clinical outcomes, or in the case of this 
study, precipitated non-adherence. Even in the few studies which have reported 
unintentional outcomes, they are presented as additional information rather than the 
primary focus of the review.   
 The Pharmacy Benefit Management Institute estimated the use of PA at 86% of 
plans and Step Therapy at 85% of plans in their 2012-2013 report.10  These interventions 
are approaching the use of tiered formularies in terms of utilization and clearly have a 
large impact on beneficiaries throughout the United States.  Therefore, the purpose of this 
review is to identify articles related to PA and Step Therapy with the intention of 
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examining reported unintended consequences of these interventions.  While not a 
comprehensive review on the topic, this review is intended to describe areas for future 
research and provide support for the importance of post-implementation review of Prior 
Authorization and Step Therapy. 
LITERATURE REVIEW 
A review of the literature was conducted by the author using multiple databases 
and references.  Initial identification of articles was made using the Academy of Managed 
Care Pharmacy (AMCP) Annotated Bibliography of Managed Care Pharmacy 
Interventions.11  This was supplemented with PubMed, Medline and Google Scholar 
searches using the terms formulary, Prior Authorization and Step Therapy.  Finally, 
contributing articles were identified by experts in managed care and an ancestral review 
of primary references.  For the purpose of this review, articles regarding inpatient PA and 
Step Therapy are excluded. 
To begin exploring PA and Step Therapy as interventions, we must first look at 
what differentiates the two.  AMCP’s somewhat complex definition for PA highlights its 
importance as a cost-saving tool in which approval is required for coverage of certain 
drugs under a benefit plan.  For patients to receive these medications, exceptions to the 
plan limitations are needed.   These exceptions are allowed under criteria developed by 
health care professionals associated with the plan.  Closely tied to PA is the intervention 
known as Step Therapy.  Categorically, this intervention is defined by AMCP as “The 
practice of beginning drug therapy for a medical condition with the most cost-effective 
and safest drug, and stepping up through a sequence of alternative drug therapies as 
preceding treatment options fail.”12  In its simplest form, Step Therapy requires that a 
first-line drug must be used before a second-line drug will be covered by the plan.  This 
process is often automated through the PBM’s online adjudication process.    
Since the primary intent of these interventions is to control cost, one would 
reasonably expect that evaluations of both interventions would rely heavily on cost 
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assessment.  In fact, Phillips and Larson suggested that methodology in 1997 as the 
primary method for measuring performance of Prior Authorization.13   
Prior Authorization 
In 1993, the first article to evaluate PA impact (Kotzan et al.) found Georgia’s 
Non-Steroidal Anti-Inflammatory Drug (NSAID) intervention to be effective at reducing 
utilization of branded COX-2 inhibitor NSAIDs and reducing overall NSAID cost.14  
Their evaluation detected an increase in the use of non-branded NSAIDs, which was to 
be expected, but the increase did not directly correspond to the reduction in branded 
NSAIDs.  When comparing the difference of these measurements, the unintended 
consequence of the PA program was a net decrease in NSAID prescriptions of 21% over 
the study period.  This decrease was accompanied by an increase in other analgesic costs 
due to increased utilization (including opioid analgesics) although the authors did not 
explain if this change in utilization corresponded to the decrease in NSAID utilization.  
Finally, the authors expected an unintended increase in utilization of nondrug services; 
however, the observed increase was not significant.  
In 1995, Smalley et al. supported these results with another NSAID PA study. 15 
Their results, in a Medicaid population similar to Kotzan’s, showed a significant 53% 
decrease in NSAID class expenditures.  Likewise, they observed an overall 19% decrease 
in NSAID use with no increase in expenditures for other medical care.  Numerous other 
studies have since validated these results for cost savings and discontinuation rates.16-21  
In September of 2002, McCombs et al. published a strikingly different study on 
effects of PA when they reviewed the revocation of PA restrictions on antidepressants.22  
Their primary measurements indicated an immediate increase in SSRI utilization after the 
removal of PA criteria.  Using regression they further estimated adherence with 
prescribed therapy, which they defined as 180 days of uninterrupted therapy.  
Surprisingly, McCombs et al. found a significant decrease in adherence following the 
removal of the PA criteria.  Observing this unexpected result, they hypothesized that 
providers were less selective in their prescribing of antidepressants after the removal of 
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PA criteria and therefore, corresponding adherence rates were lower implying that PA 
criteria improve adherence.  
Some efforts have been made to specifically address the effects of PA policies on 
outcomes other than cost.  In 2002, Momani et al. published a quasi-experimental study 
on the effect of NSAID PA on Quality of Life (QoL).23  Through a survey of 181 
individuals using the Arthritis Impact Measurement Scale (AIMS), they were able to 
estimate QoL over a 2-month period following PA intervention.  Their comparison 
groups were comprised of those who were mandated generic treatment by the 
intervention and those who received the brand-name product. Momani et al.  
demonstrated no significant effect on QoL after implementation of the PA program.  
Since the groups were comprised of subjects identified through receipt of medication, no 
weight or acknowledgement was given to the effect of the intervention on the patients’ 
ability to receive medication. Therefore, this result may be better ascribed to a test of 
brand versus generic than the results of the intervention since their groups did not include 
members who received no medication due to the intervention.   
Brown et al. have published information regarding physician burden based on 
focus groups and testing of a Burden of Prior Authorization of Psychotherapeutics 
(BoPAP) scale that the researchers developed.24,25  Their information indicates an 
administrative and perceived patient care burden associated with the use of PA criteria.   
The literature on patient outcomes, however, is sparse compared to that of cost 
evaluation, and this has been identified in many reviews as a major gap in the current 
literature.  16-21 
Step Therapy 
 There is, unfortunately, less evaluative literature on Step Therapy than that for 
Prior Authorization.  This is likely due, at least in part, to the recent addition of Step 
Therapy as a PBM intervention.  It is important to recall that the intent of Step Therapy is 
not only to restrict the use of more expensive items, but also to guide therapy to safer and 
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equally or more effective products.  Therefore, one would expect the research on this 
topic to include not only information on cost savings, but on patient outcomes as well. 
 Arguably, some of the best work in the area has been done by Motheral, 
Henderson and Cox on behalf of Express Scripts Inc.26,27  Their original work in the area 
was published in two back-to-back articles in 2004.  Both of their studies included claims 
data accompanied by specific survey data for those who were affected by a Step Therapy 
intervention.  Their first study did not attempt to detect associations with drug cost 
control due to Step Therapy.  Interestingly, they did make other assessments of the 
intervention with regard to member experience.  They determined that 11% of patients 
who encountered the intervention received no medication and an additional 11% paid 
out-of-pocket for the medication.  Cox et al. followed this with a separate survey of those 
who were believed to have received no medication after a Step Therapy intervention.  
Results of this survey indicate that 12% of those believed to have received no medication 
actually received no medication.26  The remaining 88% indicated they had in fact 
received some form of medication through cash payment, use of an alternative agent or 
through an over-the-counter agent. 
 In their second study, Motheral et al. found an even higher primary non-adherence 
rate, which they defined as patients who received no medication after a Step Therapy 
intervention.27  They indicated that 17% received no medication after a Step Therapy 
intervention and 16% paid full price out-of-pocket.   In this study, economic analysis 
showed savings for the plan sponsor of approximately $0.83 per member per month 
(PMPM).  This savings was determined across three classes (NSAID, Selective Serotonin 
Receptor Inhibitor [SSRI] and Proton Pump Inhibitor [PPI]) of which one (SSRI) showed 
no significant savings.  Additionally, the savings included a $0.10 (PMPM) 
administrative fee for the intervention.  Of important note, Motheral et al. did identify the 
need to include nondrug medical cost in future Step Therapy research. 
 In 2005, Panzer et al. modeled the research proposed by Motheral and concluded 
that there would be increased medical cost associated with SSRI Generic Step Therapy,28  
but it was Mark et al. in 2009 who ultimately studied the effect.29  They too found a drug 
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cost savings of about 3.1%, but the unintended consequence was a 7.9% reduction in 
days of antihypertensive medication supplied and a primary non-adherence rate of 6.6%.  
Additionally, Mark et al. found an increased spending of $99 per user per quarter when 
incorporating all health expenditures.   
 A review of Step Therapy research would not be complete without mentioning the 
study by Yokoyama et al. in 2007.30  Their review of Angiotensin Receptor Blocker 
(ARB) Step Therapy supported previous assertions of cost savings due to Step Therapy.  
Their observed savings of $0.03 PMPM in the 1-year review, however, was less than 
previously reported results.  This well executed study by Yokoyama et al. also 
documented a 7% primary non-adherence rate.  Finally, and quite interestingly, they 
showed that 45% of patients initially denied an ARB due to Step Therapy ultimately 
received an ARB within 12 months of the intervention.  
Limitations of the Review  
Review of the literature on pharmacy interventions is a somewhat challenging 
task because of the large amount of literature on the topic of managed care pharmacy 
interventions.  Particularly, the literature on use of a formulary or use of a tiered 
formulary contains a large number of studies.  Additionally, various outcome 
measurements and assessment methods are used to evaluate the interventions.  
Compounding the issue, many interventions overlap.  For example, the use of PA can be 
enforced with use of a third formulary tier.   In this scenario, non-preferred drug agents 
are placed in a higher copayment tier until the prior authorization criteria are met.  After 
the PA criteria are met the item is moved down to a lower copayment tier.  In 
examination of published articles, it is sometimes difficult to ascertain the effect that 
placing a drug in the third tier has versus complete lack of coverage.   
 Unfortunately, although there is a great deal of literature on some managed care 
pharmacy interventions the literature on PA and Step Therapy is sparse.  The literature on 
PA and Step Therapy interventions may be lacking in outcomes research due to the 
complexity of the information required.  Since these studies include outcomes, the 
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availability of claims and medical data is a likely limitation for many researchers.  
Additionally, cause:effect analyses of these interventions require longitudinal data for 
comparison.  With multiple outcomes and multiple interventions taking place, it will 
likely be difficult to fully comprehend the full impact of any one formulary decision.  All 
of these factors contribute to the lack of outcomes research on Prior Authorization and 
Step Therapy interventions.   
PHARMACY IN THE DEPARTMENT OF DEFENSE 
In Fiscal Year (FY) 2005, the Department of Defense (DoD) implemented 
Congressional legislation mandating a formulary control program aimed at reducing 
pharmacy spending.31  At that time, spending for the pharmacy benefit was 
approximately $5.4B with an average cost for each beneficiary of $587. 32  Since then the 
DoD has made aggressive moves to decrease per beneficiary spending.  Through actions 
of the DoD Pharmacy and Therapeutics Committee (P&T), spending in FY11 was limited 
to $6.7B and $695 per beneficiary after retail rebates.  When distributed across years 
evenly, this represents an annual increase of 4% for medication costs, which is 
comparable to the national average for drug cost inflation.33  Their stringent formulary 
controls have been well outlined by Trice et al.34   They explain the rigorous clinical and 
financial evaluation of agents the DoD applies in their use of Tiered Formulary, Prior 
Authorization and Step Therapy. 
 This review examines the effects of Step Therapy intervention in four specific 
classes of medications which have been reviewed by the DoD.35-38   The four classes to 
be reviewed are: Antihyperlipidemics (specifically the HMG Co-A Reductase Inhibitors), 
Angiotensin Receptor Blockers (ARBs), uro-selective alpha-blockers, and Dipeptidyl 
Peptidase-4 Inhibitors (DPP-4s). These classes were selected because the criteria for Step 
Therapy have remained stable over time and there is sufficient longitudinal data for the 
review.  Additionally, they have been selected due to the lack of over-the-counter (OTC) 
products available to treat the disease states.  Presence of OTC products, such as with the 
PPI class, can make examination of non-adherence based on claims difficult to validate.   
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 An overview of the Step Therapy classes is presented in Table 1.1.  Step two 
agents will receive a rejection if a claim has not been processed for any of the first step 
agents.  Claims will be paid if the patient has a previous paid prescription for the second 
step agent; therefore, this intervention is targeted at patients who are naïve to the therapy.   
The LIP-1 class expands on these criteria by also including a potency-based step 
approach.  This criterion, however, has been excluded in this research because our 
primary measured outcome is discontinuation rates. 
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Class Step Two Agents First Step Agents Implementation Date 
Antihyperlidipemics (LIP-1) fluvastatin lovastatin 27-Sep-10 
  lovastatin pravastatin   
  pitavastatin simvastatin   
  niacin/lovastatin atorvastatin   
  amlodipine/atorvastatin     
  niacin/simvastatin     
  ezetimibe/simvastatin     
  rosuvastatin     
Uroselective Alpha Blockers silodosin alfuzosin 4-Aug-10 
    tamsulosin   
Dipeptidyl Peptidase-4 
Inhibitors (DPP-4) saxagliptin metformin 13-Apr-11 
sitagliptin chlorpropramide   
linagliptin glimeprimide   
    glipizide   
    glyburide   
    tolzamide   
    tolbutamide   
    pioglitazone/metformin   
    rosiglitazone/metformin   
    rosiglitazone/glimeprimide   
    repaglinide/metformin   
    pioglitazone/glimeprimde   
Angiotensin Receptor 
Blockers (ARBs) aliskiren (alone or in combo) losartan (alone or in combo) 12-Jan-11 
candesartan (alone or in combo) telmisartan (alone or in combo)   
  eprosartan (alone or in combo) valsartan (alone or in combo)   
  irbesartan (alone or in combo)     
  olmesartan (alone or in combo)     
  azilisartan (alone or in combo)     
Table 1.1: Medications classes subject to Step Therapy in the DoD 
The DoD’s implementation of Step Therapy includes real-time pharmacy 
adjudication of Step Therapy adherence and offers messaging to pharmacies on 
appropriate step guidelines.  These guidelines have been established separately for each 
of the examined classes.39-44  To date, no DoD data has been published on the 
effectiveness of Step Therapy from a clinical or financial standpoint.  One study, by 
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Linton et al., examined utilization after implementation of PPI Prior Authorization. 21 
While under the PA umbrella, these criteria functioned much like Step Therapy in that 
they required use of preferred PPIs before the non-preferred agent was covered.  Non-
preferred agents in Linton et al.’s study were not excluded from payment, as is the case 
with DoD Step Therapy, but rather fell into a third copayment tier.  Their study reported 
that while PPI utilization rates increased, the use of the non-preferred agent decreased 
substantially following implementation of the intervention. 
RATIONALE FOR THE STUDY 
Over the past 20 years, the pharmacy benefit for many insurance companies has 
taken on increasing levels of complexity to control costs.  With some contention,45,46 
there is strong evidence to suggest overall cost savings with Prior Authorization 
interventions.  According to the PA literature, these savings appear to be attributed to 
decreased utilization of non-preferred agents and little to no increase in nondrug costs.  
Step Therapy research provides less clear cut conclusions but indicates a similar trend 
towards drug cost savings. 
 While the Step Therapy literature is yet to deliver solid evidence on intervention 
cost savings, researchers have begun to demonstrate stronger rigor in their assessment of 
PBM interventions.  Particularly, researchers have highlighted an increasingly obvious 
subset of patients who do not receive therapy after encountering Step Therapy 
intervention.  While those patients have been termed primary non-adherent, it is a 
somewhat inadequate term.  Because those patients have been, in a sense, denied claim 
coverage, they are separate from those typically defined as non-adherent (i.e., those who 
choose to not receive medication).  At the very least, the non-adherence of this population 
has been precipitated by the intervention of Step Therapy, hence the term Precipitated 
Primary Non-Adherence is applied in the current study.  It is possible that this undefined 
group actually represents an overprescribed segment of the population not requiring 
medication as suggested by McCombs22, but further research is needed in this area to 
support that conclusion.  Regardless, it is clear that upwards of 8% of Step Therapy 
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patients do not receive prescribed treatment due to the Step Therapy intervention and the 
clinical impact of this is yet to be determined. Unfortunately, the literature is weak in the 
assessment of non-cost outcomes for patients.  With cost savings thoroughly evaluated, 
the calls for more patient outcome-based investigation16-21 must be answered.  
Finally, it should be noted that a majority of the research in this area has been 
conducted in the NSAID, PPI and SSRI classes.  In an effort to further control costs, 
however, Step Therapy and PA are now being applied to a variety of classes.35-38 With 
Motheral finding varying results based on class27, it is difficult to estimate effectiveness 
of the intervention.   In 1996, Horn also suggested that outcomes will differ based on 
disease treatment class.47 Finally, with documented PA approval rates above 95%48, it is 
plausible to believe this intervention has a limited impact overall.   
The intended metric would provide a method for timely identification of patients 
with precipitated primary non-adherence (PPNA).  This would allow PBMs or 
pharmacies to make targeted interventions to ensure that the intended therapy is 
delivered.  Additionally, PPNA rates across medication classes evaluated in this study 
will provide better insight for unintended consequences of Step Therapy interventions 
and provide information for the future evaluation of other medication classes. 
PURPOSE AND OBJECTIVES 
The purpose of this study is to evaluate PPNA for four medication classes in the 
DoD population.  For these analyses, PPNA is defined as patients who did not receive a 
paid claim within the therapeutic class in the 180 days following rejection of a claim due 
to failure to meet Step Therapy criteria.  Adherent patients will be those who receive a 
paid claim for a medication in a corresponding therapeutic class following rejection due 
to failure to meet Step Therapy criteria.  
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Objectives and Hypotheses 
1. Compare the likelihood of PPNA by medication class. 
H01: The likelihood of PPNA for the specified medication classes does not 
differ significantly from the likelihood of PPNA for patients receiving a 
LIP-1 agent. 
2. Compare the likelihood of PPNA by Age Category, Sex, Beneficiary Category, 
Branch of Service, and Service Category. 
H02: The likelihood of PPNA for the specified age categories does not differ 
significantly from the likelihood of PPNA for patients in the 18-44 age 
group in the LIP-1 sample. 
 H03: The likelihood of PPNA for the specified age categories does not differ 
significantly from the likelihood of PPNA for patients in the 18-44 age 
group in the Alpha Blocker sample. 
H04: The likelihood of PPNA for the specified age categories does not differ 
significantly from the likelihood of PPNA for patients in the 18-44 age 
group in the DPP-4 sample. 
H05: The likelihood of PPNA for the specified age categories does not differ 
significantly from the likelihood of PPNA for patients in the 18-44 age 
group in the ARB sample. 
H06: The likelihood of PPNA for the specified age categories does not differ 
significantly from the likelihood of PPNA for patients in the 18-44 age 
group in the combined sample. 
H07: There is no difference in likelihood of PPNA associated with gender in 
the LIP-1 sample. 
H08: There is no difference in likelihood of PPNA associated with gender in 
the Alpha Blocker sample. 
H09: There is no difference in likelihood of PPNA associated with gender in 
the DPP-4 sample. 
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H010: There is no difference in likelihood of PPNA associated with gender in 
the ARB sample. 
H011: There is no difference in likelihood of PPNA associated with gender in 
the combined sample. 
H012: The likelihood of PPNA for the specified beneficiary categories does not 
differ significantly from the likelihood of PPNA for patients in the Active 
Duty Family member (ADF) group in the LIP-1 sample. 
H013: The likelihood of PPNA for the specified beneficiary categories does not 
differ significantly from the likelihood of PPNA for patients in the Active 
Duty Family member (ADF) group in the Alpha Blocker sample. 
H014: The likelihood of PPNA for the specified beneficiary categories does not 
differ significantly from the likelihood of PPNA for patients in the Active 
Duty Family member (ADF) group in the DPP-4 sample. 
H015: The likelihood of PPNA for the specified beneficiary categories does not 
differ significantly from the likelihood of PPNA for patients in the Active 
Duty Family member (ADF) group in the ARB sample. 
H016: The likelihood of PPNA for the specified beneficiary categories does not 
differ significantly from the likelihood of PPNA for patients in the Active 
Duty Family member (ADF) group in the combined sample. 
H017: The likelihood of PPNA for the specified branches of service does not 
differ significantly from the likelihood of PPNA for patients in the Army 
in the LIP-1 sample. 
H018: The likelihood of PPNA for the specified branches of service does not 
differ significantly from the likelihood of PPNA for patients in the Army 
in the Alpha Blocker sample. 
H019: The likelihood of PPNA for the specified branches of service does not 
differ significantly from the likelihood of PPNA for patients in the Army 
in the DPP-4 sample. 
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H020: The likelihood of PPNA for the specified branches of service does not 
differ significantly from the likelihood of PPNA for patients in the Army 
in the ARB sample. 
H021: The likelihood of PPNA for the specified branches of service does not 
differ significantly from the likelihood of PPNA for patients in the Army 
in the combined sample. 
H022: There is no difference in likelihood of PPNA associated with service 
category in the LIP-1 sample. 
H023: There is no difference in likelihood of PPNA associated with service 
category in the Alpha Blocker sample. 
H024: There is no difference in likelihood of PPNA associated with service 
category in the DPP-4 sample. 
H025: There is no difference in likelihood of PPNA associated with service 
category in the ARB sample. 
H026: There is no difference in likelihood of PPNA associated with service 
category in the combined sample. 
3. Within each drug class, determine the PPNA percentage for each of the drug agents. 
4. For adherent patients, provide statistics describing the time between initial rejected 
claim and first subsequent paid claim.  These statistics will include the mean, median, 
mode, standard deviation, 95th and 99th percentiles.  Report for the combined sample 
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Chapter Two: Methods 
This chapter describes the data source, study population, variables of interest, data 
manipulation, and data analyses that were used to meet the study objectives. 
DATA SOURCE 
The data source for this research was the DoD Pharmacy Data Transaction 
Service (PDTS) warehouse.  This warehouse was established in 2000 as a source for 
pharmacy claims in the DoD system.  In addition to holding claim transaction data, items 
are fed from various databases.  Some elements attach to the claim data, while others 
reside in separate attached databases and are called forth on each query.  The feeding 
databases for this warehouse include the National Council for Prescription Drug 
Programs (NCPDP), Defense Enrollment Eligibility Report System (DEERS), and First 
Data Bank (FDB).1   The NCPDP database contains pharmacy identifying information, 
including: type of pharmacy (retail, community, mail order, etc.), pharmacy location, and 
NCPDP ID number.  The DEERS database contains Tricare eligibility data and patient-
specific information, including the DEERS ID, date of birth, service status, and sex.  First 
Data Bank contains information relating to the drug.  Specifically of interest here are 
National Drug Code (NDC), Generic Code 4 digit (GC4), and Generic Code Number 
(GCN). 
STUDY POPULATION 
The target population for this study was comprised of patients, 18 and older, with 
prescription claims information stored in the Department of Defense (DoD) Pharmacy 
Data Transaction Service (PDTS) warehouse who encountered a Step Therapy 
intervention (rejection) while seeking payment for prescription medications in the 
previously defined classes.  This study included data for patients of all ages including 
Active Duty (AD) Service Members, Family Member Dependents, Retirees and Retiree 
Dependents who received their medication from a retail pharmacy or from home delivery 
(mail order) service.  It did not include patients who received their prescriptions from a 
 20 
Military Treatment Facility (MTF) because the MTF does not receive online adjudication 
of claims from PDTS.  Patients who used Other Health Insurance (OHI) as their primary 
payer were not included in the research, since PDTS does not reject claims as the 
secondary payer.  Additionally, patients who had processed paper claims for agents in the 
drug class were not included due to significant potential delays in processing.  Subjects 
were identified if they experience a rejection within the first 90 days after implementation 
of the step therapy criteria.  Those subjects were then followed for an additional 180 days 
after the rejection. 
STUDY VARIABLES 
Data for numerous variables were collected, recoded, and manipulated to create 
the analytic dataset used in this study.  A complete list of variables and their definitions 
are described in Appendix A.  Of particular interest are the following variables used to 
describe the sample and the results.  Explanations here are a representation of formal 
database definitions as provided by the DoD.1 
A majority of collected demographic data is populated in the PDTS database from 
the DEERS database.  These elements include the subject’s gender, beneficiary group, 
sponsor’s (service member of the family) branch of service, and age category.  For 
subject beneficiary group there are 3 primary classes each with 2 subsets.  The primary 
classes are Active Duty, Retired and Non Active Duty.  Active Duty members are those 
who are currently serving in one of the armed forces.  Retired members are those who 
have completed 20 years of active military service, or have other special circumstances 
(e.g., Medal of Honor Hero) that make them eligible for lifetime medical care without 20 
years of service.  Finally, Non-Active Duty service members are those who are not fully 
active, but are temporarily eligible for Tricare benefits (e.g., Reservists currently active).  
Within each of these primary classes subjects are categorized as either service member 
(S) or family member (F).  Family members are those who are eligible for services due to 
their relationship with the service member. 
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The sponsor’s branch of service category is related to the service the eligible 
member is associated with.  For retired subjects, this is the service from which he or she 
retired.  The primary categories for this are Army, Air Force, Coast Guard, Department of 
Defense, Public Health Service, National Oceanic and Atmospheric Association (NOAA) 
and Navy.  Due to low subject frequencies in the Coast Guard, Public Health Service and 
NOAA, these categories were aggregated by the researcher to form an “Other Services” 
category. 
Age category is provided by DEERS in a number of subsets ranging from 0 to 
65+.  Given the disease states under consideration in this research, a majority of subjects 
fell within the 45-64 age category or the 65+ age category.  With this in mind, split age 
categories less than 45 were combined to form an 18-44 age category. 
Data was also collected on point of service for the claim.  This data is based on 
pharmacy data populated from the claim and defined by the NCPDP pharmacy database.  
The categories examined in this research were Retail, Mail Order, Medical Treatment 
Facility (MTF), Veteran’s Affairs (VA CHDR), and within Theater.  Within Theater is 
comprised of soldiers receiving documented care while deployed. 
Claim-specific data was populated directly to the database from the contracted 
claim adjudicator. The three primary elements used in defining the dataset were the claim 
status, reject code, and date of claim.  Claim status and date of claim are true to their 
titles in that they indicate whether a claim was paid or rejected and on what date this 
event occurred.  The reject code is used for rejected claims to indicate the reason the 
claims adjudicator did not approve payment for the claim.  For this research, the reject 
code of interest is code 75, which indicates a claim was not paid due to failure to meet 
Step Therapy criteria.  Additionally populated in the claim adjudication process are 
indicators for paper claims (DMRindicator) and coordination with a third party insurer 
(COBindicator). These elements were used in this research to operationalize exclusionary 
criteria. 
Finally, drug class data within PDTS is built from linked data in the FDB 
database.  This class data included GC4 codes as well as GCN numbers.  GC4 codes 
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represent a primary ingredient for a medication.  For example, a GC4 code of M4DA 
indicates a primary ingredient of simvastatin.  This includes all doses and formulations of 
simvastatin.  A GCN number is more specific in that it specifies certain formulations of a 
drug ingredient.  This is particularly useful in medications that are available as a generic 
in one formulation, but brand name in another.  For example, lovastatin (Mevacor) may 
be a covered item due to its generic availability, but lovastatin (Altoprev) is not a covered 
item.  For purposes of this research, GCN# was used for analyses where a higher degree 
of differentiation was needed. 
As noted in Chapter One, the DoD employs Step Therapy based on GC4 and 
GCN codes.  During claim adjudication, all claims for a Step 2 agent are first examined 
to see if a Step 1 agent has been used.  This process is completed using the GC4 or GCN# 
for the agent being adjudicated as well as agents within the subject’s previous use profile.  
For purposes of this study, the GC4 codes and GCN#s used for adjudication are listed in 
Tables 2.1 through 2.4. 
Step 2 (Rejected) GC4s Step 2 (Rejected) GCN #s 













(lovastatin - Altoprev) 
M4DB  
(lovastatin - Mevacor) 
 A9AJ  
(atorvastatin/amlodipine) 
17652  
(lovastatin - Altoprev) 
M4DC 
(pravastatin) 




(lovastatin - Altoprev) 
M4DE 
(atorvastatin)   
M4FR  
(simvastatin/ezetimibe)       
M4DG 
(rosuvastatin)       
Table 2.1: Data codes for LIP-1 class 
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Step 2 (Rejected) 
GC4s 
Step 2 (Rejected) 
GCN #s 












(silodosin)   
48191 
(tamsulosin) 
Table 2.2: Data codes for Uro-selective Alpha Blockers 
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First Step (Prior 

























    C4KE (glyburide) 
20313  
(rosiglitazone/metformin) 
    C4KD (tolzamide) 
20314  
(rosiglitazone/metformin) 
    C4KB (tolbutamide) 
91741  
(rosiglitazone/metformin) 
      
91742  
(rosiglitazone/metformin) 
      
91743  
(rosiglitazone/metformin) 
      
98489  
(rosiglitazone/glimeprimide) 
      
97648  
(rosiglitazone/glimeprimide) 
      
26126  
(rosiglitazone/glimeprimide) 
   
26127  
(rosiglitazone/glimeprimide) 
   
16085  
(repaglinide/metformin) 
   
16084  
(repaglinide/metformin) 
   
97181  
(pioglitazone/glimeprimide) 








Step 2 (Rejected) 
GCN #s 
First Step (Prior 

























































      
22631   
(valsartan/amlodipine/hctz) 
 
      
22649   
(valsartan/amlodipine/hctz) 
 
      
22705  
(valsartan/amlodipine/hctz) 
Table 2.4: Data codes for ARBs 
DATA ANALYSIS 
STATA version 11 was used for data analyses.  The complete data analysis 
sequence is available in Appendix 2 and STATA coding for the analysis in Appendix 3. 
Initially, data were cleaned to remove observations that met exclusionary criteria 
after which demographic data for the subjects was compiled.  Following this, the criteria 
for defining PPNA were operationalized creating a dichotomous variable.  Subjects who 
did not receive a paid claim within days of initial rejection were classified as PPNA.  
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Subjects who did have a paid claim within the specified time were determined as 
adherent and a time to fill variable was calculated.   
With PPNA defined, likelihood of PPNA for each medication class was compared 
to the reference category to determine differences. Within each class, logistic regression 
analysis was used to determine association between demographic data and PPNA.  The 
regression models were tested for goodness of fit as well as violation of assumptions.  
Finally, for patients who were determined to be adherent, time to fill statistics were 
analyzed. 
REVIEW OF HYPOTHESES 
Logistic regression analyses were used to test all comparative hypotheses.  Alpha 
was set at 0.01.  This value for alpha was selected to provide a strong control of type I 










Chapter Three: Results 
This chapter describes the results of analysis for rejected drug claims due to Step 
Therapy failure in each individual drug class, as well as an aggregation of individuals 
from all classes. 
BASIC COMPOSITION OF THE DATASETS 
Table 3.1 shows the breakdown of processed claims by point of service.  
Reflective of the general DoD claims distribution, a majority of the claims were 
processed through the retail pharmacy channel.  This sample includes all processed 
claims within the specified time period, in the specified medications classes, for patients 

























































































*Total not equal to 100% due to rounding 
Table 3.1 Frequency of Processed Claims by Point of Service and Medication Class.   
Exclusion Criteria 
 After collection of data predefined exclusion criteria were applied.  Table 3.2 lists 
the criteria applied and the number of subjects excluded for each criterion.  Below the 
listed frequency, in parentheses, is the percentage of total subjects.  The first column 
listed shows subjects who were included in the initial data pull, but did not meet age 
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criteria defined in the study proposal.  The second column shows the number of subjects 
who were excluded if they filed a claim with other health insurance (OHI) at any point 
during the study period. Subjects with OHI were excluded because they are exempt from 
Step Therapy criteria.   A relatively small number of subjects were excluded because 
gender or beneficiary group information was not available.  Those who had filed a paper 
claim were excluded because substantial delays between medication dispensing and 
adjudication may exist as allowed by the pharmacy benefit.  Subjects who had a branch 
of service outside of the U.S. military were excluded, as this was not the population of 
interest.   Finally, the primary exclusion was for subjects whose claim was rejected 
outside of the study window previously defined as within 90 days of Step Therapy 
implementation.   For the combined data set, all subjects were included even if they 
occurred in more than one class. Post-hoc analysis showed that 137 subjects were present 
in 2 classes, but no subjects were in more than 2 classes.  Given the small number of 


















































































































*Total not equal to 100% due to rounding 
Table 3.2 Frequencies of Subjects Excluded by Exclusion Criteria and Medication Class 
Demographic Data 
 Following the removal of subjects based on the exclusion criteria, analyses were 
conducted on the remaining subjects to describe the general demographics of the sample.  
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Age categories were combined as previously described; as anticipated, a majority of all 
subjects analyzed were 65 years old or older. Table 3.3 describes the breakdown of 
subjects by age for each class as well as the combined sample.  For each of these groups, 
it is important to note that all of these subjects received a rejection for failure to meet 
Step Therapy criteria. 
 













































*Total not equal to 100% due to rounding 
Table 3.3 Frequencies of Subjects in the Study Sample by Age Group and Medication 
Class 
 Patient gender, as demonstrated in Table 3.4, was distributed near 50/50 in the 
LIP-1 class and in the DPP-4 class.  There was a slight skew towards females in the ARB 
class with only 40% being male.  As expected the Alpha Blocker class was 







































Table 3.4 Frequencies of Subjects in the Study Sample by Gender and Medication Class  
 Beneficiary group data (Table 3.5) and branch of service data (Table 3.6) showed no 
surprising results, with a majority of all subjects being retirees.  Specifically, the Alpha 
Blockers were almost exclusively retired service members.  This matches expectations 
due to etiology of the disease and the observation that most service members in the 
retiree segment are male.  The distribution of subjects was relatively even across 
branches of service with the exceptions being the Marine Corps and Other services.  This 
































































































Table 3.5 Frequencies of Subjects in the Study Sample by Beneficiary Group and 
Medication Class 
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*Total not equal to 100% due to rounding 
Table 3.6 Frequencies of Subjects in the Study Sample by Sponsor’s Branch of Service 
and Medication Class  
ANALYSIS OF OBJECTIVES 
After initial description of each class, objectives and hypotheses were addressed 
sequentially.  Each of the objectives, with corresponding hypotheses, is listed below. 
Objective 1 
 The purpose of objective 1 was to calculate the likelihood of PPNA in each of the 
medication classes as well as for the combined sample and compare to the likelihood for 
the LIP-1 class.  The combined sample contained 27,202 subjects who experienced a 
rejection, of whom 4,107 (15.1%) were determined to be primary non adherent.  The 
PPNA proportions varied across medication classes from 13.1% to 19.5% with the lowest 
non-adherence rates belonging to the LIP-1 class and the highest to the Alpha Blocker 
class. 
 The null hypothesis for this objective stated the likelihood of PPNA for the 
specified medication classes did not differ significantly from the likelihood of PPNA for 
patients receiving a LIP-1 agent.  Based on the logistic regression analysis by class, we 
can reject this hypothesis.  In fact, subjects in the Alpha Blocker, DPP-4, and ARB 
classes all were statistically more likely to be PPNA when compared to the LIP-1 class.  
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Subjects who received a rejection on their Alpha Blocker medication were 60% more 











OR 99% CI 
LIP-1 16,511 2,166 13.1% -Ref- -Ref- 
Alpha Blockers 660 129 19.5% 1.60* 1.22 - 2.09 
DPP-4 2,121 384 18.1% 1.43* 1.22 – 1.68 
ARB 7,910 1,428 18.1% 1.47* 1.34 – 1.62  
Combined 27,202 4,107 15.1% N/A N/A 
*Denotes statistical significance 
Table 3.7 Logistic Regression Results:  PPNA by Medication Class 
Objective 2 
 The second objective was to determine the association of various demographic 
variables with PPNA.  Five independent variables were analyzed for this objective: age, 
gender, beneficiary group, branch of service, and claim point of service.  These analyses 
were conducted by medication class using a logistic regression analysis to determine odds 
ratios and test for differences. Since there was the potential for multicollinearity between 
age and beneficiary category, all of the analyses were initially tested using the variance 
inflation factor (VIF).  VIF values (Table 3.8) are all far below 10, so the influence of 
multicollinearity was not determined to be significant. 
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VIF LIP-1 Alpha Blockers DPP-4 ARB Combined 
Beneficiary 
Group 
1.41 1.05 1.32 1.42 1.41 
Sex 1.19 1.05 1.19 1.20 1.20 
Service 
Category 
1.04 1.01 1.02 1.03 1.03 




1.01 1.01 1.00 1.01 1.01 
Mean VIF 1.18 1.04 1.14 1.18 1.17 
Table 3.8 Variance Inflation Factors for Independent Variables by Medication Class in 
the Logistic Regression Models 
To test hypotheses on age difference, subjects were stratified into three separate 
age categories and tested by class (Table 3.9).  For each class, we tested the hypothesis 
that the older age categories were not significantly different in PPNA compared to the 18-
44 age category.  For the LIP-1 class, this hypothesis was rejected as a significantly lower 
proportion of subjects were non-adherent in the 64+ class when compared to the 
reference 18-44 age category.  The OR of 0.75 (99% CI = 0.57-0.99) indicates the older 
category was 25% less likely to be non-adherent when compared to the younger category.  
This was the only individual class that showed a statistical difference between age 
categories, however, the combined sample showed a similar result with a OR of 0.78 
(99% CI = 0.63 – 0.96) indicating PPNA rates were significantly lower in the 64+ age 





































































































*Denotes statistical significance 
Table 3.9 Logistic Regression Results: PPNA by Age Group for Each Medication Class 
 The likelihood of PPNA by gender was tested using logistic regression with Male 
subjects being the reference category.  Across each class and in the combined sample, no 































































*Denotes statistical significance 
Table 3.10 Logistic Regression Results:  PPNA by Gender for Each Medication Class 
 Testing for beneficiary category differences looked across six different categories 
for differences (Table 3.11).  The reference category for this test was active duty family 
members (ADF).  For subjects in the Alpha Blocker, ARB, and DPP-4 classes there were 
no detected significant differences.  Similarly, there were no detectable differences for 
Active Duty Service members (ADS), Non-Active Duty Family members (NADF) or 
Retirees (RET) in the individual medication classes.  In the LIP-1 class and the combined 
sample, ORs were significantly lower for the Non-Active Duty Service members (NADS) 
(0.55 and 0.60, respectively).  A significant difference was also detected in the combined 
sample for Retiree Family members (RETF) (OR = 0.69, 99% CI = 0.54 – 0.90). 
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 The test by branch of service (Table 3.12) only yielded one significant result 
across all medication classes and service categories.  That difference was demonstrated in 
the LIP-1 class, and showed that Air Force subjects were less likely than Army subjects 
to be primary non-adherent (OR = 0.85).  This difference was not reproduced in any other 
















































































































































































*Denotes statistical significance 






















































































































































*Denotes statistical significance 
Table 3.12 Logistic Regression Results: PPNA by Branch of Service for Each Medication Class 
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 The final analysis of this objective was to examine differences between the Retail 
and Mail Order points of service (Table 3.13).  In both of the largest classes, LIP-1 and 
ARB, differences were detected.  Each case demonstrated Retail subjects to be nearly 
twice as likely to be non-adherent when compared to Mail Order subjects.  This result 
was confirmed with a statistically significant result (OR = 1.90, 95% CI = 1.69 – 2.13) in 


























































*Denotes statistical significance 
Table 3.13 Logistic Regression Results: PPNA by Service Category for Each Medication 
Class 
Objective 3 
The third objective was, for each class, to describe the proportion of subjects who 
were PPNA for each of the medications. The data provides important insight as to the 
most commonly rejected medications and the resilience of the subjects to adhere to 
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therapy following the rejection.  Tables 3.14 through 3.17 present the data for each class 
and the agents within that class.  Generally, agents within the class appeared 












amlodipine/atorvastatin 276 40 14.5% 
ezetimibe/simvastatin 2,547 308 12.1% 
fluvastatin sodium 177 18 10.2% 
lovastatin 17 0 0.0% 
niacin/lovastatin 86 10 11.6% 
niacin/simvastatin 565 78 13.8% 
pitavastatin calcium 867 179 20.6% 
rosuvastatin calcium 11,976 1,533 12.8% 
OVERALL 16,511 2,166 13.1% 
  
  


















silodosin 660 129 19.5% 














linagliptin 39 7 17.9% 
pioglitazone/glimeprimide 1 0 0.0% 
pioglitazone/metformin 7 1 14.3% 
rosiglitazone/metformin 2 0 0.0% 
saxagliptin 312 66 21.2% 
saxagliptin/metformin 114 19 16.7% 
sitagliptin/metformin 519 78 15.0% 
sitagliptin 1,127 213 18.9% 
OVERALL 2,121 384 18.1% 
  
  













aliskiren hemifurate 748 181 24.2% 
aliskiren/amlodipine 34 7  20.6% 
aliskiren/amldopine/HCTZ 4 2 50.0% 
aliskiren/HCTZ 143 25 17.5% 
aliskiren/valsarten 262 65 24.8% 
amlodipine/olmesartan 616 141 22.9% 
azilsartan medoxomil 6 1 16.7% 
candesarten cilexetil 491 70 14.3% 
eprosartan 9 6 66.7% 
eprosartan/HCTZ 5 5 100.0% 
irbesartan 999 161 16.1% 
irbesartan/HCTZ 268 53 19.8% 
olmesartan/amlodipine 295 84 28.5% 
olmesartan medoxomil 2,222 387 17.4% 
olmesartan/HCTZ 1,604 219 13.7% 
OVERALL 7,910 1,428 13.1% 
  
  
Table 3.17 PPNA Proportions for Medications in the ARB Class 
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Objective 4 
The final objective is designed to describe the days to fill for subjects who were 
met with a rejection, but later filled a prescription for an agent in the same therapeutic 
class.  Most importantly, this objective seeks to determine the mathematical 
characteristics of the time between rejection and first fill. 
 Table 3.18 describes the values for the time to fill statistic and Figures 3.1 through 
3.5 demonstrate the distribution of values.  The histograms show values to be strongly 
skewed to the right.  Statistical values confirm this with a median value of 7 days, but a 










































19.7 7 31.5 92 155 
Table 3.18 Days to Fill Statistics for Adherent Patients  
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Figure 3.1 Histogram of Days until Adherence for the LIP-1 Class 
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Figure 3.3 Histogram of Days until Adherence for the DPP4 Class 
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Figure 3.5 Histogram of Days until Adherence for the Combined Data 
 
 
Summary of Hypotheses 
 
 Table 3.19 contains a summary of the hypotheses tests. For a majority of 
hypotheses, we failed to reject the null hypothesis.  Significant differences were found 
between medication classes as well as in multiple samples for age category, beneficiary 
category, and point of service.   
 
 Hypothesis Result 
H01 
The likelihood of PPNA for the specified medication 
classes does not differ significantly from the likelihood of 
PPNA for patients receiving a LIP-1 agent. 
Rejected 
H02 
The likelihood of PPNA for the specified age categories 
does not differ significantly from the likelihood of PPNA 
for patients in the 18-44 age group in the LIP-1 sample. 
Rejected 
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H03 
The likelihood of PPNA for the specified age categories 
does not differ significantly from the likelihood of PPNA 
for patients in the 18-44 age group in the Alpha Blocker 
sample. 
Failed to Reject 
H04 
The likelihood of PPNA for the specified age categories 
does not differ significantly from the likelihood of PPNA 
for patients in the 18-44 age group in the DPP-4 sample. 
Failed to Reject 
H05 
The likelihood of PPNA for the specified age categories 
does not differ significantly from the likelihood of PPNA 
for patients in the 18-44 age group in the ARB sample. 
Failed to Reject 
H06 
The likelihood of PPNA for the specified age categories 
does not differ significantly from the likelihood of PPNA 




There is no difference in likelihood of PPNA associated 
with gender in the LIP-1 sample. Failed to Reject 
H08 
There is no difference in likelihood of PPNA associated 
with gender in the Alpha Blocker sample. Failed to Reject 
H09 
There is no difference in likelihood of PPNA associated 
with gender in the DPP-4 sample. Failed to Reject 
H010 
There is no difference in likelihood of PPNA associated 
with gender in the ARB sample. Failed to Reject 
H011 
There is no difference in likelihood of PPNA associated 
with gender in the combined sample. Failed to Reject 
H012 
The likelihood of PPNA for the specified beneficiary 
categories does not differ significantly from the likelihood 
of PPNA for patients in the Active Duty Family member 
(ADF) group in the LIP-1 sample. 
Rejected 
H013 
The likelihood of PPNA for the specified beneficiary 
categories does not differ significantly from the likelihood 
of PPNA for patients in the Active Duty Family member 
(ADF) group in the Alpha Blocker sample. 
Failed to Reject 
H014 
The likelihood of PPNA for the specified beneficiary 
categories does not differ significantly from the likelihood 
of PPNA for patients in the Active Duty Family member 
(ADF) group in the DPP-4 sample. 
Failed to Reject 







The likelihood of PPNA for the specified beneficiary 
categories does not differ significantly from the likelihood 
of PPNA for patients in the Active Duty Family member 
(ADF) group in the ARB sample. 
Failed to Reject 
H016 
The likelihood of PPNA for the specified beneficiary 
categories does not differ significantly from the likelihood 
of PPNA for patients in the Active Duty Family member 
(ADF) group in the combined sample. 
Rejected 
H017 
The likelihood of PPNA for the specified branches of 
service does not differ significantly from the likelihood of 
PPNA for patients in the Army in the LIP-1 sample. 
Rejected 
H018 
The likelihood of PPNA for the specified branches of 
service does not differ significantly from the likelihood of 
PPNA for patients in the Army in the Alpha Blocker 
sample. 
Failed to Reject 
H019 
The likelihood of PPNA for the specified branches of 
service does not differ significantly from the likelihood of 
PPNA for patients in the Army in the DPP-4 sample. 
Failed to Reject 
H020 
The likelihood of PPNA for the specified branches of 
service does not differ significantly from the likelihood of 
PPNA for patients in the Army in the ARB sample. 
Failed to Reject 
H021 
The likelihood of PPNA for the specified branches of 
service does not differ significantly from the likelihood of 
PPNA for patients in the Army in the combined sample 
Failed to Reject 
H022 
There is no difference in likelihood of PPNA associated 
with service category in the LIP-1 sample. Rejected 
H023 
There is no difference in likelihood of PPNA associated 
with service category in the Alpha Blocker sample. Failed to Reject 
H024 
There is no difference in likelihood of PPNA associated 
with service category in the DPP-4 sample. Failed to Reject 
H025 
There is no difference in likelihood of PPNA associated 
with service category in the ARB sample. Rejected 
H026 
There is no difference in likelihood of PPNA associated 
with service category in the combined sample. Rejected 
Table 3.19 Continued 
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Chapter Four: Discussion 
The final chapter of this thesis provides interpretations of the results related to the 
objectives, seeks to identify the strengths and limitations of the research methodology, 
discusses the implications of the results, and identifies opportunities for future research.   
RESULTS RELATIVE TO OBJECTIVES 
Objective 1 
 The observed rate of PPNA for this objective overall (15.1%) initially seems in 
line with previous results.  The rates for the Motheral and Cox studies were similar at 
11% and 17% respectively, but these studies were conducted through survey 
methodology. 1,2 The only other claims-based study, by Yokoyama et al., found the rate 
to be 7%, about half the observed rate of this study.3  If we focus on the ARB class, 
which was the class used by Yokoyama et al., we see a PPNA rate of over 18%.   
This drastic difference in rates is attributed to three primary factors.  First, in the 
Yokoyama study the follow-on to initial rejection was 1 year versus the 180-day follow-
on for this study.3  Second, Yokoyama documented PPNA as failure to receive any 
antihypertensive medication.  In this study, PPNA was documented as failure to receive a 
step-appropriate agent.  Finally, the Yokoyama study was comprised of 8,904 subjects 
who experienced a rejection versus this study which was comprised of 27,202 subjects.    
Examining the first factor, follow-on period, one could assert that the 180-day 
follow-on is more clinically appropriate than a 1-year follow-on.  For antihypertensive 
therapy, it seems undesirable that patient therapy would be delayed for more than 6 
months.  Regarding the second factor, the intention of step therapy should be examined.  
Not only is the intent to control cost, but also to guide prescribing to the best therapeutic 
alternative.  The use of any antihypertensive is not always a suitable alternative for use of 
an ARB.  The Yokoyama study assumed that ARB therapy could be replaced with any 
antihypertensive.3  For this study, it was assumed that only an ACEI or an ARB would be 
a suitable substitute for the initially prescribed ARB.  Finally, consideration should be 
given to the fact that this study encompassed multiple classes and a large sample size, 
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which helps to mitigate clinical considerations such as those described in ARB 
substitution.  Considering all of these factors, the combined PPNA rate of 15.1% seems 
to be a reasonable representation of the overall PPNA rate for Step Therapy intervention. 
To the author’s knowledge, this is the largest evaluation of non-adherence 
following step therapy ever conducted.  Additionally, it was the only identified claims-
based study that examined multiple medication classes.  In light of this, it is not currently 
possible to couch results of this study in previous findings.  Interestingly, different PPNA 
rates were observed when comparing the Alpha Blocker, DPP-4, and ARB classes to the 
LIP-1 class.  Given the etiology of each disease, it could be expected that the LIP-1 class 
would have the highest PPNA rate, however, the inverse is true.  This could be attributed 
to two  possible reasons.  First, the LIP-1 class was the first of these classes to have step 
therapy implemented.  It is possible that patients and providers responded more acutely in 
the initial rollout of this program.  Second, LIP-1 agents have a very large amount of 
direct-to-consumer advertising.  Therefore, these agents could be viewed by patients as 
more necessary than drugs in the other classes.  If this is in fact the case, then future 
research could evaluate the effect of advertising expenditures on PPNA rate.  The LIP-1 
PPNA rate clearly influences the combined PPNA rate due to its difference from the 
other agents and the large sample size.  Because of this large sample size, it should 
certainly be included in the combined rate despite its outlier status.  As a class, LIP-1s 
accounted for over 65% of the total sample while ARBs as the second largest class only 
accounted for about 25%. 
Objective 2 
 For this objective, again there was no identified literature which examined the 
association between various demographic factors and likelihood of PPNA.  Due to the 
scarcity of previous research, these results must once again stand alone for interpretation.   
Looking first at the non-significant findings, gender and branch of service did not seem to 
be associated with any difference in likelihood for PPNA.  Age 64+ and retired family 
members did seem to have a somewhat lower likelihood of PPNA than the younger and 
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active duty family member populations, respectively.  The association here was identified 
in the combined sample, but not uniformly in the drug classes, indicating there could be a 
small association not readily identified in smaller group sizes.  The appearance of the 
association in these groups could be attributed to a higher self awareness of health, or 
possibly more free time to navigate the requirements of the step therapy process. 
 The most drastic and uniform association was the nearly double likelihood of 
PPNA in retail claims compared to mail order claims.  The cause of this association is not 
clearly evident, but possibly lies within the varying procedures to address step therapy 
rejections.  It is known that standard operating procedure exists in the mail order 
pharmacy to address these rejections, but it is less consistent for the retail sector.  
Regardless of cause, the association is drastic and further consideration and research 
should be given to this topic. 
Objective 3 
 This objective did not reveal any particularly surprising statistics, however will 
serve as a good DoD reference for the utilization and rejection rates of these agents.   
Objective 4 
 The final objective looked at the adherent proportion of this sample.  Specifically, 
the objective identified the time to adherence after an initial rejection.  Not surprisingly, a 
large segment of those who are adherent reach adherence in the first week as indicated by 
a median of 6 to 7 days.  After the initial surge, the rate of adherence drops significantly 
with 95th and 99th percentiles not reached until 90 and 150 days, respectively.  This 
information could prove useful as consideration is given to interventions aimed at 
lowering the PPNA rate.  Particularly, it identifies a point of intervention that would be 
most impactful 7 days or later after the rejection.  
LIMITATIONS 
 First, and most apparently, this study is limited by the design.  As a retrospective 
database analysis, no causality assumptions can be made.  Additionally, randomization 
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did not occur and the groups cannot be assumed to be equivalent.  The DoD sample also 
may also not be representative of the general population for these diseases.   
 The calculation of PPNA rates also cannot be assumed to be exact.  There is the 
possibility that some patients identified as PPNA did in fact receive therapy.  This could 
have been through another medication that was not included in analysis or through use of 
another payment source not identified (e.g., cash).   
Finally, there was no measurement of the consequence of PPNA.  Clearly the 
most important consideration of adherence is the impact on the health of the non-adherent 
subjects.  No assessment was made in this study and no assertions can be made due to 
that design.  In addition to health, no economic impacts were studied.  From this study, it 
cannot be determined if step therapy resulted in overall plan cost avoidance. 
FUTURE RESEARCH 
 This study demonstrated a need for further research on the unintentional 
consequences of step therapy.  Now that a group has been identified who is non-adherent 
after the intervention, it would be interesting to note if this resulted in adverse clinical 
outcomes.  One possible approach to this would be to examine blood glucose differences 
in subjects identified as PPNA for the DPP-4 category.  A comparison could also be 
made to determine the level of blood glucose control for patients who were switched to 
metformin as a result of the step therapy.   
Additionally, there appears to be a strong association between point of service and 
PPNA.  Future research should be directed to this difference and possibly testing of new 
interventions to affect the difference.  It would appear from the data presented here that 
the highest impact interventions would focus on patients who have not received an agent 
within 7 days of rejection and received care in the retail sector. 
CONCLUSIONS 
 It appears that over 15% of patients who experience a step therapy rejection will 
not receive a similar medication within 180 days.  Those who receive their care from a 
retail pharmacy are nearly twice as likely to be non-adherent when compared to mail 
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order patients.  Finally, of the group who become adherent after the initial rejection, half 
of them will receive a medication with the first 7 days after the rejection. The remaining 
non-adherent subjects represent a subset that deserves further consideration.  Particularly, 
research should begin on the clinical implications of non-adherence.  Pharmacy Benefit 
Managers should give consideration to this and the financial implication of non-
adherence when implementing Step Therapy in their plans.  
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age String Age category of the 
beneficiary at the time 









age_rec Numeric Recoded Age 1 = 0-4 
2 = 5-14 
7 = 15-17 
3 = 18-24 
4 = 25-34 
5 = 35-44 
6 = 45-64 
8 = 65+ 





















bengroup_rec Numeric Recode of bengroup 1 = ADF 
2 = ADS 
3 = NADF 
4 = NADS 
5 = RET 
6 = RETF 
7 = UNK 
birthdate String Patient's Date of Birth - 
Dropped from all data 
sets 
5/2/1979 
brandname String The brand name of the 
drug for claim filed 
Lipitor 
claimstatus String For each claim indicates 
Paid or Rejected 
Paid 
Rejected 
claimstatus_rec Numeric Recode of claimstatus 1 = Paid 
2 = Rejected 
cobindicator2 String Coordination of benefit 
indicator.  Indicates if 
the claim was filed with 
other health insurance. 
Y = Yes 










cobindicator_rec Numeric Recode of cobindicator2 1 = No 
2 = Yes 
cobindicator_rev Numeric A reverse of the 
cobindicator, used to 
place claims with other 
health insurance first for 
purpose of exclusion of 
subjects from sample 
1 = Yes 
2 = No 
compoundcode String Indicates if the product 
dispensed was a 
compounded product 
N = No 
Y = Yes 
NS = Not Sent 
comptime Numeric Researcher calculated 
variable measuring the 
time, in days, between 
initial claim rejection 
and subsequent paid 
claim. 
7 
cutoffdate Numeric Researcher calculated 
variable  set as the date 
of implementation plus 
90 
 
datedispensed String Date prescription was 
filled 
10/12/2010 
datedispensed_rec Date/Time Recode of the date 
dispensed variable to fit 
STATA time 
10/12/2010 
















dayssupply Numeric Days supply of the 
prescription calculated 
by the transmitting site's 
system 
90 
deersid String Patient's unique ID 
number for claims 
processing 
123456789 
dmrindicator String Indicates if the claim 
was processed as a paper 
filed claim, rather than 
electronically.  
N = No 
Y = Yes 
dmrindicator_rec Numeric Recode of dmrindicator 1 = No 
2 = Yes 
dmrindicator_rev Numeric A reverse of the 
dmrindicator, used to 
paper filed claims are 
listed first for purposes 
of subject removal 
1 = Yes 
2 = No 
dosageform String Description of the drug 
form 
Tablet 
dropindicator Numeric Researcher defined 
variable indicating if the 
patient meets criteria to 
be dropped from the 
study sample 
0 = No 









firstmerge String Stata defined variable 
which indicates the 
results of the first merge 
procedure during 
analysis 
_1 = Only present in 
Master 
_2 = Present other than 
Master 
_3 = Present in more than 
1 dataset 
gc3description String Description of drug 
grouping 
Cardiovascular 
gc4 String Code indicating primary 
ingredient within First 
Data Bank (FDB) 
A1AA 
GCN Numeric Generic Code Number 
which is specific to the 
generic ingredient, 
dosage form and strength 
35741 
gcnsequencenumber Numeric Random number from 
PDTS representing the 
generic formulation 
8348 
genericindicator String Identifies drug as multi-
source or single source.  
Brand or Generic 
N = Unavailable 
O = Originator, generics 
available 
Y = Generic 
genericname String Generic name of the 
drug filed with the claim 
atorvastatin 
genericname_paid String Generic name value for 
paid claims 
atorvastatin 
genericname_rej String Generic name value for 










ndc Numeric National Drug Code as 
filed with the FDA 
12345678901 
otcindicator String Indetifies the drug filed 
as non-legend 
Y = Yes 
N = No 
pastcutoff Numeric Researcher defined 
variable indicating if the 
datedispensed is past the 
defined cutoff date 
0 = No 
1 = Yes 
ppna Numeric Researcher defined 
variable indicating if the 
patient meets the criteria 
of precipitated primary 
non-adherence as 
evidenced by a rejected 
claim with no subsequent 
paid claim with 180 days 
0 = No 
1 = Yes 
processeddatetime String Date and time the claim 
was processed by the 
adjudicator 
10/12/2010 14:23 
quantitydispensed Numeric Quantity of medication 
processed with the claim 
90 
rejcomp Numeric Researcher defined 
variable indicating the 
patient encountered a 
rejection and received a 
paid claim for another 
agent within 180 days 
0 = No 










rejectcode1 Numeric For rejected claims, 
indicates the reason for 
rejection 
75 = Failure of Step 
Therapy 
rejectcode2 Numeric For rejected claims, 
indicates the reason for 
rejection 
75 = Failure of Step 
Therapy 
rejectcode3 Numeric For rejected claims, 
indicates the reason for 
rejection 
75 = Failure of Step 
Therapy 
servicecategoryclaim String Indicates the point of 
service the claim was 
processed at 




Theater = By military 
personnel at a location 
other than MTF 
VA CHDR = Processed 
by the VA for patients 
who are eligible for both 
VA and DOD benefits 
servicecategoryclaim_paid Numeric Value of the 
servicecategoryclaim_re
c for paid claims 
1 = MTF 
2 = Mail Order 
3 = Retail 
4 = Theater 










servicecategoryclaim_rec Numeric Recode of 
servicecategoryclaim 
1 = MTF 
2 = Mail Order 
3 = Retail 
4 = Theater 
5 = VA CHDR 
servicecategoryclaim_rej Numeric Value of the 
servicecategoryclaim_rec 
for rejected claims 
1 = MTF 
2 = Mail Order 
3 = Retail 
4 = Theater 
5 = VA CHDR 
sex String Gender of the patient at 
the time of the last PDTS 
transaction 
F = Female 
M = Male 
. = Not on file 
sex_rec Numeric Recode of sex 1 = Female 
2 = Male 
sponsorbranchofservice String The branch of service to 
which the sponsor 
belongs at the time of the 
last PDTS transaction 
A = Army 
C = Coast Guard 
D = Office of SecDef 
F = Air Force 
H = Public Health Service 
M = Marine Corps 
N = Navy 
O = Nat Oceanic/Atmos 
1 = Foreign Army 
2 = Foreign Navy 
3 = Foreign Marine Corps 
4 = Foreign Air Force 
X = Not Applicable 









sponsorbranchofservice_rec Numeric Recode of 
sponsorbranchofservice 
1 = A 
2 = C 
3 = D 
4 = F 
5 = H 
6 = M 
7 = N 
8 = O 
9 = X  
. = . 
strength String The strength of the 
medication processed in 
the claim 
10 
_merge Numeric Stata defined variable 
which indicates the 
results of the second 
merge procedure during 
analysis 
_1 = Only present in 
Master 
_2 = Present other than 
Master 
_3 = Present in more than 
1 dataset 
Table A1: Variables included in data analysis 
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APPENDIX B Complete Analysis Sequence 
Recoding of the String Variables 
1. Working from the original working 1 table, variables listed below were recoded 









2. Original, unrecoded, variables or variables not of interest to final analysis were 
dropped from the table. 
3. Table saved as working 2. 
Description of the Complete Sample 
1. Starting with the table working 2, observations were sorted first by deersid and 
then within deersid by beneficiary group, paper claim indicator, and other health 
insurance (OHI) indicator. 
2. Only the first observation was retained for each deersid, certain to retain a claim 
that was a paper claim and/or was as an OHI claim, if one existed. 
3. Descriptive variables were tabulated to describe the complete sample. 
4. After initial analysis, a drop variable was constructed and populated with a value 
of 1 for individuals who met the following criteria: 
• Subjects with a cobindicator_rec value indicating the use of OHI. 
• Subjects with a dmrindicator_rec value indicating they had filed a paper 
claim. 
• Subjects with in an age category below 18 years old. 
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• Subjects with a missing gender value. 
• Subjects with in a beneficiary group listed as “other”. 
• Subjects whose sponsor branch of service was listed as NOAA, not 
applicable or missing. 
5. Table saved as working 3. 
Construction of the Study Sample 
1. Starting with the working 2 table, values of the for the drop indicator were 
merged into each observation using the deersid as the link. 
2. All observations containing a drop indicator of 1 were removed.   
3. Table saved as working 4. 
Description of the Study Sample 
1. Starting with the table working 4, observations were sorted by deersid. 
2. The first observation was retained for each deersid. 
3. Descriptive variables were tabulated to describe the study sample. 
4. The constructed table was saved as working 5. 
Construction of the Reject Table 
1. Starting with the table working 4, only rejected claims were retained. 
2. Claims were then sorted by deersid and date dispensed. 
3. The first observation for each deersid was retained for analysis. 
4. A cutoffdate variable was created for each observation equal to the date of 
implementation plus 90 days. 
5. A variable was created and populated with 1 for observations with a date 
processed greater than the cutoff date. 
6. Variables for date processed, service category, and generic name were recoded for 
association with rejected claims. 
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7. Using “Keep” logic, retain only the first rejection for each patient.  This step is 
used to eliminate redundant submission of a rejected claim resulting in a single 
claim for each patient in a given class. 
8. Descriptive variables were tabulated to describe the sample of subjects with 
rejected claims, not including those who had rejection date beyond the cutoff 
period. 
9. This table saved as reject 1 included the claims which were beyond the cutoff 
period. 
Construction of the Paid Table 
1. Starting with the table working 4, only paid claims were retained. 
2. Variables for date processed, service category, and generic name were recoded for 
association with paid claims. 
3. The table was saved as paid 1. 
Merger of the Paid and Rejected Tables 
1. Starting with the table paid 1, the unique rejected claim from reject 1 was merged 
to any matching paid claims by deersid. 
2. Observations with a pastcutoff value of 1 from the rejected table were dropped 
from the analysis. 
3. Variable for time to adherence (comptime) was created and calculated by taking 
the difference of the paid date and the rejected date. 
4. Observations were sorted by deersid and comptime. 
5. The first observation for each deersid with the lowest comptime was retained. 
6. For subjects with no paid date or a comptime greater than 180 days, a PPNA 
variable was created and populated with 1. 
7. For subjects other than PPNA a variable (rejcomp) was created and populated 
with a 1. 
8. Table was saved as merged. 
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Analysis of the PPNA Subjects 
1. Starting with the merged table, only subjects with a PPNA value equal to 1 were 
retained. 
2. Descriptive variables were tabulated to describe the sample of subjects. 
3. Table saved as PPNA. 
Analysis of the Adherent Subjects 
1. Starting with the merged table, only subjects with a PPNA value equal to 1 were 
retained. 
2. Descriptive variables were tabulated to describe the sample of subjects. 
3. The comptime variable was described according to range, mean, and standard 
deviations. 
4. The comptime variable was analyzed by percentiles and plotted as a histograph 
for further description 
5. Table saved as rejcomp. 
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Appendix 3: Sample of STATA Code 
*coding.do 
clear 
insheet using "Q:\Step Therapy Analysis Data\LIP-1\working1.txt" 
save "Q:\Step Therapy Analysis Data\LIP-1\Working1.dta", replace 














encode age, generate (age_rec) 
replace age_rec = 3 if (age_rec == 4) 
replace age_rec = 3 if (age_rec == 5) 
label define agel 1 "Ages 0 - 4" 2 "Ages 15 - 17" 3 "Ages 18 - 44" 6 
"Ages 45-64" 7 "Ages 5 - 14" 8 "Ages 65+" 
label values age_rec agel 
codebook age_rec 
encode cobindicator, generate (cobindicator_rec) 
codebook cobindicator_rec 
encode sex, generate (sex_rec) 
codebook sex_rec 
encode servicecategoryclaim, generate (servicecategoryclaim_rec) 
codebook servicecategoryclaim_rec 
encode claimstatus, generate (claimstatus_rec) 
codebook claimstatus_rec 
encode bengroup, generate (bengroup_rec) 
codebook bengroup_rec 
encode sponsorbranchofservice, generate (sponsorbranchofservice_rec) 
*recode the branch of service groups to combine smaller groups then 
relabel 
replace sponsorbranchofservice_rec = 2 if (sponsorbranchofservice_rec 
== 3) 
replace sponsorbranchofservice_rec = 2 if (sponsorbranchofservice_rec 
== 5) 
replace sponsorbranchofservice_rec = 2 if (sponsorbranchofservice_rec 
== 8) 
label define bosl 1 "Army" 2 "Other Service" 4 "Air Force" 6 "Marine 
Corps" 7 "Navy" 9 "Not Applicable" 
label values sponsorbranchofservice_rec bosl 
codebook sponsorbranchofservice_rec 




tabulate bengroup_rec claimstatus_rec, row 
generate datedispensed_rec=date(datedispensed, "MDY") 
format datedispensed_rec %d 
drop age bengroup datedispensed sponsorbranchofservice cobindicator2 
sex servicecategoryclaim claimstatus dateprocessed genericindicator 
dmrindicator compoundcode birthdate 
save "Q:\Step Therapy Analysis Data\LIP-1\Working2.dta", replace 
 
*working3.do 
use "Q:\Step Therapy Analysis Data\LIP-1\Working2.dta", clear 
gen dmrindicator_rev = . 
replace dmrindicator_rev = 1 if dmrindicator_rec ==2 
replace dmrindicator_rev = 2 if dmrindicator_rec ==1 
gen cobindicator_rev = . 
replace cobindicator_rev = 1 if cobindicator_rec ==2 
replace cobindicator_rev = 2 if cobindicator_rec ==1 
sort deersid age_rec bengroup_rec dmrindicator_rev cobindicator_rev 
quietly by deersid: keep if _n==1 
keep deersid age_rec  cobindicator_rec sex_rec bengroup_rec 
sponsorbranchofservice_rec dmrindicator_rec  
gen cobdropindicator = 0 
replace cobdropindicator = 1 if cobindicator_rec ==2 
gen dmrdropindicator = 0 
replace dmrdropindicator = 1 if dmrindicator_rec ==2 
gen agedropindicator = 0 
replace agedropindicator = 1 if inlist(age_rec, 1,2,7) 
gen sexdropindicator = 0 
replace sexdropindicator = 1 if sex_rec ==. 
gen bendropindicator = 0 
replace bendropindicator = 1 if  bengroup_rec == 7 
gen bosdropindicator = 0 













save "Q:\Step Therapy Analysis Data\LIP-1\working3.dta", replace 
drop if agedropindicator ==1 
drop if bendropindicator ==1 
drop if dmrdropindicator ==1 
drop if cobdropindicator ==1 




use "Q:\Step Therapy Analysis Data\LIP-1\Working2.dta", clear 
sort deersid 
drop  age_rec cobindicator_rec dmrindicator_rec sex_rec bengroup_rec 
sponsorbranchofservice_rec 
merge deersid using "Q:\Step Therapy Analysis Data\LIP-1\working3.dta" 
drop if agedropindicator ==1 
drop if bendropindicator ==1 
drop if dmrdropindicator ==1 
drop if cobdropindicator ==1 
drop if bosdropindicator ==1 
codebook authorizationnumber 
gen firstmerge = _merge 
drop _merge 




*this describes the dataset without drops for out of range 
*use this and subtract reject number to get total number dropped for 
range 
use "Q:\Step Therapy Analysis Data\LIP-1\Working4.dta", clear 
keep deersid age_rec bengroup_rec sex_rec sponsorbranchofservice_rec 
sort deersid age_rec bengroup_rec  














*builds the rejected claim database and describes users 
use "Q:\Step Therapy Analysis Data\LIP-1\Working4.dta" if 
claimstatus_rec==2, clear 
codebook claimstatus_rec 
sort deersid datedispensed_rec 
quietly by deersid: keep if _n==1 
gen cutoffdate = td(6Oct2010) +90 
format cutoffdate %d 
generate pastcutoff = 0 
replace pastcutoff = 1 if datedispensed_rec > cutoffdate 
describe 
save "Q:\Step Therapy Analysis Data\LIP-1\Reject1.dta", replace 
gen date_rej = datedispensed_rec 
gen servicecategoryclaim_rej = servicecategoryclaim_rec 
gen genericname_rej = genericname 
format date_rej %d 
keep sponsorbranchofservice_rec pastcutoff deersid age_rec bengroup_rec 
sex_rec date_rej servicecategoryclaim_rej genericname_rej  
save "Q:\Step Therapy Analysis Data\LIP-1\Reject1.dta", replace 












use "Q:\Step Therapy Analysis Data\LIP-1\Working4.dta" if 
claimstatus_rec==1, clear 
codebook claimstatus_rec 
sort deersid datedispensed_rec 
gen date_paid = datedispensed_rec 
gen servicecategoryclaim_paid = servicecategoryclaim_rec 
gen genericname_paid = genericname 
format date_paid %d 
keep sponsorbranchofservice_rec date_paid deersid 
servicecategoryclaim_paid genericname_paid 




use "Q:\Step Therapy Analysis Data\LIP-1\paid1.dta", clear 
merge deersid using "Q:\Step Therapy Analysis Data\LIP-1\reject1.dta" 
drop if pastcutoff == 1 
gen ppna = 0 
gen nonrej = 0 
gen rejcomp = 0 
gen comptime = . 
replace comptime = (date_paid - date_rej) 
replace comptime = 9999 if comptime < 0 
sort deersid comptime 
quietly by deersid: keep if _n==1 
replace ppna = 1 if missing(date_paid)& date_rej > 0 
replace nonrej = 1 if missing(date_rej) 
replace ppna = 1 if comptime > 180 
replace rejcomp = 1 if nonrej < 1& ppna < 1 
replace comptime = . if comptime >180 




use "Q:\Step Therapy Analysis Data\LIP-1\merged.dta" 











use "Q:\Step Therapy Analysis Data\LIP-1\merged.dta" 









summarize comptime, detail 
hist comptime, frac 




use "Q:\Step Therapy Analysis Data\LIP-1\merged.dta", clear 
 
collin  bengroup_rec sex_rec servicecategoryclaim_rej age_rec 
sponsorbranchofservice_rec 
 
xi: logistic  ppna i.bengroup_rec i.sex_rec i.servicecategoryclaim_rej 
i.age_rec i.sponsorbranchofservice_rec 
 
 
 
